High colloid oncotic therapy for brain edema with cerebral hemorrhage.
We examined the effectiveness of high colloid oncotic pressure (COP) therapy to suppress and/or reduce brain edema associated with putaminal hemorrhage of patients whose clinical grades were grade 3 or 4a classified according to the Japanese neurological grading for putaminal hemorrhage. In the treated group of 11 patients, 25% albumin solution was intravenously administered (50-100 ml/day) with additional use of furosemide (20-40 mg/day) following hematoma removal. The serum COP was maintained at 25-30 mmHg for 2 weeks. In the untreated group of 11 patients, the COP therapy was not applied following hematoma removal. The serum COP was 20-25 mmHg for 2 weeks thereafter. During the 2-week observation period, serum osmolality, electrolyte, and hematocrit levels did not significantly differ between the two groups. The midline structure shift on CT of the treated group was 4.5 mm, which was significantly smaller than that of the untreated group (p < 0.05). The numbers of patients either in the vegetative state or death were 0 and 3, respectively, in the treated and the untreated groups. We concluded that high COP therapy for 2 weeks following hematoma removal was effective to suppress and/or reduce brain edema associated with putaminal hemorrhage, and that this therapy could be continued for 2 weeks without systemic complications.
Tone
O
O
Department of Neurosurgery, Musashino Red Cross Hospital, Tokyo, Japan.
Ito
U
U
Tomita
H
H
Masaoka
H
H
Tominaga
B
B
D000328:Adult; D000368:Aged; D000418:Albumins / Q000008:administration & dosage*; D001798:Blood Proteins / Q000378:metabolism; D001812:Blood-Brain Barrier / Q000502:physiology; D001929:Brain Edema / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D002543:Cerebral Hemorrhage / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D005665:Furosemide / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination; D011699:Putamen / Q000503:physiopathology; D015996:Survival Rate; D016896:Treatment Outcome; D014882:Water-Electrolyte Balance / Q000502:physiology
D000418:Albumins; D001798:Blood Proteins; D005665:Furosemide